Colon Cancer
Research from University of Ulsan provide new insights into colon cancer
Published in Angiogenesis Weekly, April 17th, 2009
"Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has shown clinical activity in metastatic colorectal cancer patients when used as either a first-line or second-line treatment. Here, we evaluated the efficacy and safety of bevacizumab plus FOLFIRI (irinotecan, 5-fluorouracil, and leucovorin) or FOLFOX (oxaliplatin, 5-fluorouracil, and leucovorin) in metastatic colorectal cancer cases after failure to FOLFIRI and FOLFOX," scientists writing in the journal Medical Oncology report.
"Between October 2004 and February 2007, the data on 42 patients with metastatic colorectal cancer after failure of FOLFIRI and FOLFOX were reviewed...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Angiogenesis Weekly
Source: Angiogenesis Weekly (2009-04-17)
More Articles from Angiogenesis Weekly
- Wake Forest University Baptist Medical Center
Blood protein may hold key to stopping tumor growth in cancer patients - Angiogenesis
Data on angiogenesis detailed by G.N. Naumov and co-authors - Angiogenesis
Findings in angiogenesis reported from National Heart, Lung, & Blood Institute - Angiogenesis
New angiogenesis study findings have been reported by A.D. Norden and colleagues - Angiogenesis
Report summarizes angiogenesis study findings from T.M. Zielonka and co-researchers - Angiogenesis
Report summarizes angiogenesis study findings from University of Tennessee - More from this issue of Angiogenesis Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
